Company news

Lexicon Pharmaceuticals, Inc. news in 2025

Lexicon Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

December 9, 2025

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

December 4, 2025

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

November 24, 2025

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

November 10, 2025

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

November 7, 2025

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

November 5, 2025

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

November 3, 2025

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 29, 2025

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

October 13, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

October 7, 2025

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

September 21, 2025

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

September 16, 2025

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

September 10, 2025

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

September 7, 2025

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

September 3, 2025

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

September 2, 2025

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

September 1, 2025

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

August 26, 2025

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 5, 2025

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 30, 2025

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

July 17, 2025

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 22, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 17, 2025

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 19, 2025

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 12, 2025

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

May 5, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 5, 2025

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

March 27, 2025

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

March 6, 2025

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 5, 2025

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

March 3, 2025

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

March 3, 2025

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

March 1, 2025

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

February 17, 2025

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

January 20, 2025

Lexicon Appoints Scott Coiante as Chief Financial Officer

January 1, 2025

Calls in 2025

Decks in 2025